APOL1 Induces Pyroptosis of Fibroblasts Through NLRP3/Caspase-1/GSDMD Signaling Pathway in Ulcerative Colitis

References

• Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28(1):573–621. doi:10.1146/annurev-immunol-030409-101225
   PubMedGoogle Scholar
• Shah SC, Itzkowitz SH. Colorectal cancer in inflammatory bowel disease: mechanisms and management. Gastroenterology. 2022;162(3):715–730. doi:10.1053/j.gastro.2021.10.035
   PubMed Web of Science ®Google Scholar
• Du L, Ha C. Epidemiology and pathogenesis of Ulcerative colitis. Gastroenterol Clin North Am. 2020;49(4):643–654. doi:10.1016/j.gtc.2020.07.005
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019;94(7):1357–1373. doi:10.1016/j.mayocp.2019.01.018
   PubMed Web of Science ®Google Scholar
• Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin Med. 2021;21(2):135–139. doi:10.7861/clinmed.2021-0080
   PubMed Web of Science ®Google Scholar
• Cookson BT, Brennan MA. Pro-inflammatory programmed cell death. Trends Microbiol. 2001;9(3):113–114. doi:10.1016/S0966-842X(00)01936-3
   PubMed Web of Science ®Google Scholar
• Tan G, Huang C, Chen J, et al. Gasdermin-E-mediated pyroptosis participates in the pathogenesis of Crohn’s disease by promoting intestinal inflammation. Cell Rep. 2021;35(11):109265. doi:10.1016/j.celrep.2021.109265
   PubMed Web of Science ®Google Scholar
• Shi J, Gao W, Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci. 2017;42(4):245–254. doi:10.1016/j.tibs.2016.10.004
   PubMed Web of Science ®Google Scholar
• Broz P, Pelegrin P, Shao F. The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol. 2020;20(3):143–157. doi:10.1038/s41577-019-0228-2
   PubMed Web of Science ®Google Scholar
• Burdette BE, Esparza AN, Zhu H, et al. Gasdermin D in pyroptosis. Acta Pharm Sin B. 2021;11(9):2768–2782. doi:10.1016/j.apsb.2021.02.006
   PubMed Web of Science ®Google Scholar
• McCarthy N, Kraiczy J, Shivdasani RA. Cellular and molecular architecture of the intestinal stem cell niche. Nat Cell Biol. 2020;22(9):1033–1041. doi:10.1038/s41556-020-0567-z
   PubMed Web of Science ®Google Scholar
• Koliaraki V, Prados A, Armaka M, et al. The mesenchymal context in inflammation, immunity and cancer. Nat Immunol. 2020;21(9):974–982. doi:10.1038/s41590-020-0741-2
   PubMed Web of Science ®Google Scholar
• Davidson S, Coles M, Thomas T, et al. Fibroblasts as immune regulators in infection, inflammation and cancer. Nat Rev Immunol. 2021;21(11):704–717. doi:10.1038/s41577-021-00540-z
   PubMed Web of Science ®Google Scholar
• Wang X, Liotta L. Clinical bioinformatics: a new emerging science. J Clin Bioinforma. 2011;1(1):1. doi:10.1186/2043-9113-1-1
   PubMedGoogle Scholar
• Xie K, Kong S, Li F, et al. Bioinformatics-based study to investigate potential differentially expressed genes and miRNAs in pediatric sepsis. Med Sci Monit. 2020;26:e923881. doi:10.12659/MSM.923881
   PubMed Web of Science ®Google Scholar
• Chen R, Lai LA, Brentnall TA, et al. Biomarkers for colitis-associated colorectal cancer. World J Gastroenterol. 2016;22(35):7882–7891. doi:10.3748/wjg.v22.i35.7882
   PubMed Web of Science ®Google Scholar
• Anashkina AA, Leberfarb EY, Orlov YL. Recent trends in cancer genomics and bioinformatics tools development. Int J Mol Sci. 2021;22(22):12146. doi:10.3390/ijms222212146
   PubMed Web of Science ®Google Scholar
• Korbecki J, Maruszewska A, Bosiacki M, et al. The potential importance of CXCL1 in the physiological state and in noncancer diseases of the cardiovascular system, respiratory system and skin. Int J Mol Sci. 2022;24(1):205. doi:10.3390/ijms24010205
   PubMed Web of Science ®Google Scholar
• Tzukerman M, Shamai Y, Abramovich I, et al. Comparative analysis of the APOL1 variants in the genetic landscape of renal carcinoma cells. Cancers. 2022;14(3):733. doi:10.3390/cancers14030733
   PubMed Web of Science ®Google Scholar
• O’Toole JF, Schilling W, Kunze D, et al. ApoL1 overexpression drives variant-independent cytotoxicity. J Am Soc Nephrol. 2018;29(3):869–879. doi:10.1681/ASN.2016121322
   PubMed Web of Science ®Google Scholar
• Wakashin H, Heymann J, Roshanravan H, et al. APOL1 renal risk variants exacerbate podocyte injury by increasing inflammatory stress. BMC Nephrol. 2020;21(1):371. doi:10.1186/s12882-020-01995-3
   PubMed Web of Science ®Google Scholar
• Wu J, Raman A, Coffey NJ, et al. The key role of NLRP3 and STING in APOL1-associated podocytopathy. J Clin Invest. 2021;131(20). doi:10.1172/JCI136329
   Web of Science ®Google Scholar
• Wei K, Nguyen HN, Brenner MB. Fibroblast pathology in inflammatory diseases. J Clin Invest. 2021;131(20). doi:10.1172/JCI149538
   Web of Science ®Google Scholar
• Sinha S, Sparks HD, Labit E, et al. Fibroblast inflammatory priming determines regenerative versus fibrotic skin repair in reindeer. Cell. 2022;185(25):4717–4736. doi:10.1016/j.cell.2022.11.004
   PubMed Web of Science ®Google Scholar
• Komatsu N, Takayanagi H. Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions. Nat Rev Rheumatol. 2022;18(7):415–429. doi:10.1038/s41584-022-00793-5
   PubMed Web of Science ®Google Scholar
• Dokoshi T, Seidman JS, Cavagnero KJ, et al. Skin inflammation activates intestinal stromal fibroblasts and promotes colitis. J Clin Invest. 2021;131(21). doi:10.1172/JCI147614
   PubMed Web of Science ®Google Scholar
• Friedman DJ, Pollak MR. APOL1 and kidney disease: from genetics to Biology. Annu Rev Physiol. 2020;82(1):323–342. doi:10.1146/annurev-physiol-021119-034345
   PubMedGoogle Scholar
• Friedman DJ, Pollak MR. APOL1 nephropathy: from genetics to clinical applications. Clin J Am Soc Nephrol. 2021;16(2):294–303. doi:10.2215/CJN.15161219
   PubMed Web of Science ®Google Scholar
• Duchateau PN, Pullinger CR, Orellana RE, et al. Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J Biol Chem. 1997;272(41):25576–25582. doi:10.1074/jbc.272.41.25576
   PubMed Web of Science ®Google Scholar
• Marais AD. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. Pathology. 2019;51(2):165–176. doi:10.1016/j.pathol.2018.11.002
   PubMed Web of Science ®Google Scholar
• Noels H, Lehrke M, Vanholder R, et al. Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations. Nat Rev Nephrol. 2021;17(8):528–542. doi:10.1038/s41581-021-00423-5
   PubMed Web of Science ®Google Scholar
• Bang-Rudenstam A, Cerezo-Magana M, Belting M. Pro-metastatic functions of lipoproteins and extracellular vesicles in the acidic tumor microenvironment. Cancer Metastasis Rev. 2019;38(1–2):79–92. doi:10.1007/s10555-019-09786-5
   PubMed Web of Science ®Google Scholar
• Chen TK, Surapaneni AL, Arking DE, et al. APOL1 kidney risk variants and proteomics. Clin J Am Soc Nephrol. 2022;17(5):684–692. doi:10.2215/CJN.14701121
   PubMed Web of Science ®Google Scholar
• Parsa A, Kao WH, Xie D, et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013;369(23):2183–2196. doi:10.1056/NEJMoa1310345
   PubMed Web of Science ®Google Scholar
• Lin J, Xu Z, Xie J, et al. Oncogene APOL1 promotes proliferation and inhibits apoptosis via activating NOTCH1 signaling pathway in pancreatic cancer. Cell Death Dis. 2021;12(8):760. doi:10.1038/s41419-021-03985-1
   PubMed Web of Science ®Google Scholar
• Camba-Gomez M, Arosa L, Gualillo O, et al. Chemokines and chemokine receptors in inflammatory bowel disease: recent findings and future perspectives. Drug Discov Today. 2022;27(4):1167–1175. doi:10.1016/j.drudis.2021.12.004
   PubMed Web of Science ®Google Scholar
• Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354(6):610–621. doi:10.1056/NEJMra052723
   PubMed Web of Science ®Google Scholar
• Liu ZY, Zheng M, Li YM, et al. RIP3 promotes colitis-associated colorectal cancer by controlling tumor cell proliferation and CXCL1-induced immune suppression. Theranostics. 2019;9(12):3659–3673. doi:10.7150/thno.32126
   PubMed Web of Science ®Google Scholar
• Korbecki J, Szatkowska I, Kupnicka P, et al. The importance of CXCL1 in the physiological state and in noncancer diseases of the oral cavity and abdominal organs. Int J Mol Sci. 2022;23(13):7151. doi:10.3390/ijms23137151
   PubMed Web of Science ®Google Scholar
• Jiang S, Liang J, Li W, et al. The role of CXCL1/CXCR2 axis in neurological diseases. Int Immunopharmacol. 2023;120:110330. doi:10.1016/j.intimp.2023.110330
   PubMed Web of Science ®Google Scholar
• Wang L, Hauenstein AV. The NLRP3 inflammasome: mechanism of action, role in disease and therapies. Mol Aspects Med. 2020;76:100889. doi:10.1016/j.mam.2020.100889
   PubMed Web of Science ®Google Scholar
• Bulek K, Zhao J, Liao Y, et al. Epithelial-derived gasdermin D mediates nonlytic IL-1beta release during experimental colitis. J Clin Invest. 2020;130(8):4218–4234. doi:10.1172/JCI138103
   PubMed Web of Science ®Google Scholar